Serina Therapeutics Stock Performance
| SER Stock | 4.79 0.64 15.42% |
The entity has a beta of -0.87, which indicates possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Serina Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Serina Therapeutics is expected to outperform it slightly. At this point, Serina Therapeutics has a negative expected return of -0.0552%. Please make sure to validate Serina Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Serina Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Serina Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable technical and fundamental indicators, Serina Therapeutics is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
Actual Historical Performance (%)
One Day Return 15.42 | Five Day Return (5.52) | Year To Date Return (67.98) | Ten Year Return (95.05) | All Time Return (95.05) |
Last Split Factor 28:1000 | Last Split Date 2024-03-15 |
1 | Employers Have A Responsibility To Address Age Stereotypes | 09/27/2024 |
2 | Bidens top aides denied he was disintegrating asdonors warned prezs aging appearance was f--king up campaign book | 10/10/2024 |
3 | Acquisition by Harris J Milton of 40000 shares of Serina Therapeutics at 11.828 subject to Rule 16b-3 | 10/14/2024 |
4 | Market Highlights McDonalds, Starbucks slump as gold nears 2,750 ASX to open higher | 10/22/2024 |
5 | Tom Hanks, 68, reveals the surprising age he absolutely hated Your bones start wearing off | 11/01/2024 |
6 | Serina Therapeutics Inc trading resumes - TipRanks | 11/07/2024 |
7 | Acquisition by Mintz Steven of 5000 shares of Serina Therapeutics at 9.5 subject to Rule 16b-3 | 11/11/2024 |
8 | Acquisition by Bailey Gregory of 1776 shares of Serina Therapeutics at 8.25 subject to Rule 16b-3 | 11/15/2024 |
9 | Worlds oldest man, John Tinniswood, dies at 112 | 11/26/2024 |
10 | ALPHA AESTHETICS PARTNERS ANNOUNCES STRATEGIC PARTNERSHIP WITH CAROLINA AGE MANAGEMENT INSTITUTE , LED BY DR. STEPHEN GIORDANO | 12/03/2024 |
11 | Jennifer Lopez interviewer awkwardly calls out her age Did he just say that | 12/17/2024 |
| Begin Period Cash Flow | 645 K |
Serina |
Serina Therapeutics Relative Risk vs. Return Landscape
If you would invest 596.00 in Serina Therapeutics on September 19, 2024 and sell it today you would lose (117.00) from holding Serina Therapeutics or give up 19.63% of portfolio value over 90 days. Serina Therapeutics is generating negative expected returns assuming volatility of 7.92% on return distribution over 90 days investment horizon. In other words, 70% of stocks are less volatile than Serina, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Serina Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Serina Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Serina Therapeutics, and traders can use it to determine the average amount a Serina Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.007
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SER |
Estimated Market Risk
| 7.92 actual daily | 70 70% of assets are less volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Serina Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Serina Therapeutics by adding Serina Therapeutics to a well-diversified portfolio.
Serina Therapeutics Fundamentals Growth
Serina Stock prices reflect investors' perceptions of the future prospects and financial health of Serina Therapeutics, and Serina Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Serina Stock performance.
| Return On Asset | -0.45 | ||||
| Profit Margin | (2.21) % | ||||
| Operating Margin | (75.80) % | ||||
| Current Valuation | 62.84 M | ||||
| Shares Outstanding | 8.88 M | ||||
| Price To Sales | 18.03 X | ||||
| Revenue | 142 K | ||||
| EBITDA | (9.78 M) | ||||
| Net Income | (14.8 M) | ||||
| Total Debt | 4.37 M | ||||
| Book Value Per Share | (1.86) X | ||||
| Cash Flow From Operations | (7.8 M) | ||||
| Earnings Per Share | 0.14 X | ||||
| Market Capitalization | 57.2 M | ||||
| Total Asset | 11.96 M | ||||
| Retained Earnings | (131.01 M) | ||||
| Working Capital | 110.89 K | ||||
About Serina Therapeutics Performance
Assessing Serina Therapeutics' fundamental ratios provides investors with valuable insights into Serina Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Serina Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -5.2 K | -5.4 K | |
| Return On Tangible Assets | (1.30) | (1.37) | |
| Return On Capital Employed | (1.65) | (1.56) | |
| Return On Assets | (1.24) | (1.30) | |
| Return On Equity | (2.71) | (2.57) |
Things to note about Serina Therapeutics performance evaluation
Checking the ongoing alerts about Serina Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Serina Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Serina Therapeutics generated a negative expected return over the last 90 days | |
| Serina Therapeutics has high historical volatility and very poor performance | |
| Serina Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Serina Therapeutics was previously known as AgeX Therapeutics and was traded on NYSE MKT Exchange under the symbol AGE. | |
| The company reported the last year's revenue of 142 K. Reported Net Loss for the year was (14.8 M) with profit before taxes, overhead, and interest of 0. | |
| Serina Therapeutics generates negative cash flow from operations | |
| Serina Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 58.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from nypost.com: Jennifer Lopez interviewer awkwardly calls out her age Did he just say that |
- Analyzing Serina Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Serina Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Serina Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Serina Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Serina Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Serina Therapeutics' stock. These opinions can provide insight into Serina Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.